Centrix, a specialty pharmaceutical company focused on Pediatrics and Women’s Health, is all set to launch Clofera during the fourth quarter. Clofera is indicated for the temporary relief of cough and nasal congestion due to the common cold, hay fever, or other upper respiratory allergies.
Clofera contains a non-narcotic antitussive – chlophedianol hydrochloride, in addition to nasal decongestant – pseudoephedrine hydrochloride.
The company claims that the product is specifically formulated without dyes, sugar, alcohol or gluten to meet particular consumer needs and address patient sensitivities.
John Booth, president and CEO of Centrix, said: We are pleased to introduce Clofera to temporarily control the cough reflex, therefore reducing the intensity of coughing with a product that is free of narcotic effects. Clofera provides physicians with another therapeutic option in the management of cough and congestion associated with allergic rhinitis or the common cold. The release of Clofera further compliments our goal to develop and expand the Centrix specialty portfolio.